MARKET

EDIT

EDIT

Editas Medicine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.96
-1.04
-4.95%
After Hours: 20.75 +0.79 +3.96% 18:19 03/27 EDT
OPEN
20.48
PREV CLOSE
21.00
HIGH
20.86
LOW
19.70
VOLUME
919.14K
TURNOVER
--
52 WEEK HIGH
34.37
52 WEEK LOW
14.01
MARKET CAP
1.10B
P/E (TTM)
-7.4692
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EDIT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EDIT stock price target is 35.86 with a high estimate of 55.00 and a low estimate of 28.00.

EPS

EDIT News

More
  • Editas (EDIT) Up 0.1% Since Last Earnings Report: Can It Continue?
  • Zacks · 2d ago
  • Sangamo Therapeutics: Market Cap Is At A Bargain Relative To Its Cash Position
  • Seeking Alpha - Article · 4d ago
  • Editas Medicine (EDIT) Catches Eye: Stock Jumps 9%
  • Zacks · 03/19 15:40
  • Edited Transcript of EDIT earnings conference call or presentation 26-Feb-20 10:00pm GMT
  • Thomson Reuters StreetEvents · 03/11 22:11

Industry

Biotechnology & Medical Research
-2.44%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About EDIT

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).
More

Webull offers kinds of Editas Medicine Inc stock information, including NASDAQ:EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions.